EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

Arianna Di Stadio, Salvatore Gallina, Salvatore Cocuzza, Pietro De Luca, Angelo Ingrassia, Simone Oliva, Federico Sireci, Angelo Camaioni, Fabio Ferreli, Giuseppe Mercante, Francesca Gaino, Gian Marco Pace und 2 weitere

European Archives of Oto-Rhino-Laryngology · 2023

DOI: 10.1007/s00405-023-08085-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2023. Verfasst von Arianna Di Stadio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com. Hauptthemen laut MEDLINE: COVID-19, Olfaction Disorders. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Catania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Few evidence-based therapies are available for chronic olfactory dysfunction after COVID-19. This study investigated the relative efficacy of olfactory training alone, co-ultramicronized palmitoylethanolamide with luteolin (um-PEA–LUT, an anti-neuroinflammatory supplement) alone, or combined therapy for treating chronic olfactory dysfunction from COVID-19.

Methods

This double-blinded controlled, placebo-controlled multicenter randomized clinical trial was conducted in 202 patients with persistent COVID-19 olfactory dysfunction of > 6 month duration. After a screening nasal endoscopy, patients were randomized to: (1) olfactory training and placebo; (2) once daily um-PEA–LUT alone; (3) twice daily um-PEA–LUT alone; or (4) combination of once daily um-PEA–LUT with olfactory training. Olfactory testing (Sniffin’ Sticks odor identification test) was performed at baseline and at 1, 2, and 3 months. The primary outcome was recovery of over three points on olfactory testing, with outcomes compared at T 0 , T 1 , T 2 and T 3 across groups. Statistical analyses included one-way ANOVA for numeric data and chi-square for nominal data.

Results

All patients completed the study, and there were no adverse events. At 90 days, odor identification scores improved by > 3 points in 89.2% of patients receiving combined therapy vs. 36.8% receiving olfactory training with placebo, 40% receiving twice daily um-PEA–LUT alone, and 41.6% receiving once daily um-PEA–LUT alone ( p < 0.00001). Patients receiving treatment with um-PEA–LUT alone demonstrated subclinical improvement (< 3 point odor identification improvement) more often than patients receiving olfactory training with placebo ( p < 0.0001.)

Conclusions

Olfactory training plus once daily um-PEA–LUT resulted in greater olfactory recovery than either therapy alone in patients with long-term olfactory function due to COVID-19.

Trial registration

20112020PGFN on clinicaltrials.gov. Level of evidence 1b (Individual Randomized Clinical Trial).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Olfaction DisordersHumansLuteolinOlfactory TrainingSmellAmidesEthanolaminesPalmitic Acids

Stichwörter der Autor:innen

AnosmiaCOVID-19Clinical trialCoronavirusHyposmiaLuteolinNeuroinflammationOlfactory trainingPEAPEA–LUTPalmitoylethanolamidePost-acute sequelae of COVID-19Randomized trialSARS-CoV-2Smell disorders

Substanzen

LuteolinpalmidrolAmidesEthanolaminesPalmitic Acids

Autor:innen und Institutionen

  • Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com.
  • Otolaryngology Department, University of Palermo, Palermo, Italy.
  • Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy.
  • Otolaryngology Department, San Giovanni-Addolorata Hospital, Rome, Italy.
  • Otolaryngology Department, Humanitas University Hospital, Milan, Italy.
  • Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.

Förderung

  • Università degli Studi di Catania

Zitieren

APA

Di Stadio, A., Gallina, S., Cocuzza, S., De Luca, P., Ingrassia, A., Oliva, S., Sireci, F., Camaioni, A., Ferreli, F., Mercante, G., Gaino, F., Pace, G. M., La Mantia, I., & Brenner, M. J. (2023). Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-023-08085-8

Vancouver

Di Stadio A, Gallina S, Cocuzza S, De Luca P, Ingrassia A, Oliva S, et al. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. European Archives of Oto-Rhino-Laryngology. 2023. doi:10.1007/s00405-023-08085-8

BibTeX
@article{DiStadio2023,
  author = {Di Stadio, Arianna and Gallina, Salvatore and Cocuzza, Salvatore and De Luca, Pietro and Ingrassia, Angelo and Oliva, Simone and Sireci, Federico and Camaioni, Angelo and Ferreli, Fabio and Mercante, Giuseppe and Gaino, Francesca and Pace, Gian Marco and La Mantia, Ignazio and Brenner, Michael J},
  title = {Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2023},
  doi = {10.1007/s00405-023-08085-8}
}
Kostenlos starten →